1
|
Abstract
The CRISPR/Cas9 system allows for site-specific gene editing and genome engineering of primary human cells. Here we describe methods for gene editing and genome engineering of B cells isolated from human peripheral blood mononuclear cells using CRISPR/Cas9. Editing frequencies of up to 90% and integration rates greater than 60% can be achieved with this method.
Collapse
Affiliation(s)
- Kanut Laoharawee
- Department of Pediatrics, Cardiovascular Research, Masonic Cancer Center, Center for Genome Engineering, University of Minnesota, Minneapolis, MN, USA
| | - Matthew J Johnson
- Department of Pediatrics, Cardiovascular Research, Masonic Cancer Center, Center for Genome Engineering, University of Minnesota, Minneapolis, MN, USA
| | - Branden S Moriarity
- Department of Pediatrics, Cardiovascular Research, Masonic Cancer Center, Center for Genome Engineering, University of Minnesota, Minneapolis, MN, USA.
| |
Collapse
|
2
|
Wu CAM, Roth TL, Baglaenko Y, Ferri DM, Brauer P, Zuniga-Pflucker JC, Rosbe KW, Wither JE, Marson A, Allen CDC. Genetic engineering in primary human B cells with CRISPR-Cas9 ribonucleoproteins. J Immunol Methods 2018; 457:33-40. [PMID: 29614266 DOI: 10.1016/j.jim.2018.03.009] [Citation(s) in RCA: 32] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2018] [Revised: 03/24/2018] [Accepted: 03/26/2018] [Indexed: 12/27/2022]
Abstract
Genome editing in human cells with targeted nucleases now enables diverse experimental and therapeutic genome engineering applications, but extension to primary human B cells remains limited. Here we report a method for targeted genetic engineering in primary human B cells, utilizing electroporation of CRISPR-Cas9 ribonucleoproteins (RNPs) to introduce gene knockout mutations at protein-coding loci with high efficiencies that in some cases exceeded 80%. Further, we demonstrate knock-in editing of targeted nucleotides with efficiency exceeding 10% through co-delivery of oligonucleotide templates for homology directed repair. We delivered Cas9 RNPs in two distinct in vitro culture systems to achieve editing in both undifferentiated B cells and activated B cells undergoing differentiation, reflecting utility in diverse experimental conditions. In summary, we demonstrate a powerful and scalable research tool for functional genetic studies of human B cell biology that may have further applications in engineered B cell therapeutics.
Collapse
Affiliation(s)
- Chung-An M Wu
- Cardiovascular Research Institute, Sandler Asthma Basic Research Center, 555 Mission Bay Blvd S, University of California, San Francisco, San Francisco, CA 94143, USA
| | - Theodore L Roth
- Department of Microbiology and Immunology, 513 Parnassus Ave, University of California, San Francisco, CA 94143, USA
| | - Yuriy Baglaenko
- Krembil Research Institute, 60 Leonard Ave, University Health Network, Toronto, Ontario, Canada; Department of Immunology, 60 Leonard Ave, University of Toronto, Toronto, Ontario, Canada
| | - Dario M Ferri
- Krembil Research Institute, 60 Leonard Ave, University Health Network, Toronto, Ontario, Canada; Department of Immunology, 60 Leonard Ave, University of Toronto, Toronto, Ontario, Canada
| | - Patrick Brauer
- Department of Immunology, 60 Leonard Ave, University of Toronto, Toronto, Ontario, Canada; Sunnybrook Research Institute, 2075 Bayview Ave, University of Toronto, Toronto, Ontario, Canada
| | - Juan Carlos Zuniga-Pflucker
- Department of Immunology, 60 Leonard Ave, University of Toronto, Toronto, Ontario, Canada; Sunnybrook Research Institute, 2075 Bayview Ave, University of Toronto, Toronto, Ontario, Canada
| | - Kristina W Rosbe
- Department of Otolaryngology, 550 16th St, University of California, San Francisco, San Francisco, CA 94143, USA
| | - Joan E Wither
- Krembil Research Institute, 60 Leonard Ave, University Health Network, Toronto, Ontario, Canada; Department of Immunology, 60 Leonard Ave, University of Toronto, Toronto, Ontario, Canada; Department of Medicine, 60 Leonard Ave, University of Toronto, Toronto, Ontario, Canada.
| | - Alexander Marson
- Department of Microbiology and Immunology, 513 Parnassus Ave, University of California, San Francisco, CA 94143, USA; Department of Medicine, Diabetes Center, Helen Diller Family Comprehensive Cancer Center, 513 Parnassus Ave, University of California, San Francisco, CA 94143, USA; Innovative Genomics Institute, 2151 Berkeley Way, University of California, Berkeley, Berkeley, CA 94720, USA; Chan Zuckerberg Biohub, 499 Illinois St, San Francisco, CA 94158, USA.
| | - Christopher D C Allen
- Cardiovascular Research Institute, Sandler Asthma Basic Research Center, 555 Mission Bay Blvd S, University of California, San Francisco, San Francisco, CA 94143, USA; Department of Anatomy, 555 Mission Bay Blvd S, University of California, San Francisco, San Francisco, CA 94143, USA.
| |
Collapse
|